Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 24;12(6):0.
doi: 10.3390/cancers12061672.

Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe

Giulia Veronesi  1   2 , David R Baldwin  3 , Claudia I Henschke  4 , Simone Ghislandi  5 , Sergio Iavicoli  6 , Matthijs Oudkerk  7 , Harry J De Koning  8 , Joseph Shemesh  9 , John K Field  10 , Javier J Zulueta  11   12 , Denis Horgan  13 , Lucia Fiestas Navarrete  5 , Maurizio Valentino Infante  14 , Pierluigi Novellis  2 , Rachael L Murray  15 , Nir Peled  16 , Cristiano Rampinelli  17 , Gaetano Rocco  18 , Witold Rzyman  19 , Giorgio Vittorio Scagliotti  20 , Martin C Tammemagi  21 , Luca Bertolaccini  22 , Natthaya Triphuridet  4   23 , Rowena Yip  4 , Alexia Rossi  24 , Suresh Senan  25 , Giuseppe Ferrante  26 , Kate Brain  27 , Carlijn van der Aalst  8 , Lorenzo Bonomo  28 , Dario Consonni  29 , Jan P Van Meerbeeck  30 , Patrick Maisonneuve  31 , Silvia Novello  20 , Anand Devaraj  32 , Zaigham Saghir  33 , Giuseppe Pelosi  34   35
Affiliations
Review

Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe

Giulia Veronesi et al. Cancers (Basel). .

Abstract

Lung cancer screening (LCS) with low-dose computed tomography (LDCT) was demonstrated in the National Lung Screening Trial (NLST) to reduce mortality from the disease. European mortality data has recently become available from the Nelson randomised controlled trial, which confirmed lung cancer mortality reductions by 26% in men and 39-61% in women. Recent studies in Europe and the USA also showed positive results in screening workers exposed to asbestos. All European experts attending the "Initiative for European Lung Screening (IELS)"-a large international group of physicians and other experts concerned with lung cancer-agreed that LDCT-LCS should be implemented in Europe. However, the economic impact of LDCT-LCS and guidelines for its effective and safe implementation still need to be formulated. To this purpose, the IELS was asked to prepare recommendations to implement LCS and examine outstanding issues. A subgroup carried out a comprehensive literature review on LDCT-LCS and presented findings at a meeting held in Milan in November 2018. The present recommendations reflect that consensus was reached.

Keywords: computed tomography; consensus; implementation; low dose; lung cancer; mortality; reduction; screening; statement.

PubMed Disclaimer

Conflict of interest statement

G.V. has financial relationships with Medtronic, Ab Medica, and Johnson & Johnson outside the submitted work. D.B. has a financial relationship with Astra Zeneca, C.H. is inventor of the patents owned by Cornell Research Foundation (CRF), she has divested herself of all royalties arising. She is also the President of the Early Diagnosis and Treatment Research Foundation. M.O. reports grants from the Royal Dutch Academy of Sciences, from the Netherlands Organisation of Scientific Research, and from the Netherlands Organisation for Health Research and Development. HJDK reports personal fees from the University of Zurich/Astra Zeneca, outside the submitted work; he is PI of the Horison 2020 EU Study 4-in-the-lung-run. J.K.F. reports financial relationship with AstraZeneca, Epigenomics; NUCLEIX Ltd., from iDNA, grants from Janssen Research & Development, LLC, outside the submitted work. J.J.Z. reports financial relationship with VisionGate. C.R. reports grants from AIRC. G.R. reports personal fees from Scanlan International. W.R. reports grants from Medical University of Gdańsk, outside the submitted work; he has a patent “A profile of blood protein markers as a test for the detection of lung cancer issued”. G.V.S. reports personal fees from Eli Lilly, Roche, AstraZeneca, MSD, Takeda. M.T. reports to have developed the PLCOm2012 lung cancer risk prediction model, which is mentioned in the article. The model is open access and available free of charge to non-commercial users. For commercial users licensing has been assigned to Brock University. To date, M.C.T. has not received any money for use of the PLCOm2012 model. S.S. reports grants and other from Varian Medical Systems, grants from ViewRay Inc, grants and personal fees from Astra Zeneca, personal fees from MSD, personal fees from Celgene, outside the submitted work. S.N. reports personal fees from Astra Zeneca, BI, MSD, Takeda, Pfizer, Roche, BMS, Abbvie, Eli Lilly, Bayer. S.G., S.I., J.S., L.F.N., M.V.I., P.N., R.L.M., P.N., L.B., N.T., R.Y., A.R., G.F., K.B., C.v.d.A., L.B., D.C., J.P.V.M., P.M., Z.S., G.P. declare no competing interests.

References

    1. Oudkerk M., Devaraj A., Vliegenthart R., Henzler T., Prosch H., Heussel C.P., Bastarrika G., Sverzellati N., Mascalchi M., Delorme S., et al. European Position Statement on Lung Cancer Screening. Lancet Oncol. 2017;18:e754–e766. doi: 10.1016/S1470-2045(17)30861-6. - DOI - PubMed
    1. De Koning H., Van Der Aalst C., Ten Haaf K., Oudkerk M. PL02.05 Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial. J. Thorac. Oncol. 2018;13:S185. doi: 10.1016/j.jtho.2018.08.012. - DOI
    1. Tammemägi M.C., Church T.R., Hocking W.G., Silvestri G.A., Kvale P.A., Riley T.L., Commins J., Berg C.D. Evaluation of the Lung Cancer Risks at Which to Screen Ever- and Never-Smokers: Screening Rules Applied to the PLCO and NLST Cohorts. PLoS Med. 2014;11:e1001764. doi: 10.1371/journal.pmed.1001764. - DOI - PMC - PubMed
    1. Kovatich A., Friedland D.M., Druck T., Hadaczek P., Huebner K., Comis R.L., Hauck W., McCue P.A. Molecular Alterations to Human Chromosome 3p Loci in Neuroendocrine Lung Tumors. Cancer. 1998;83:1109–1117. doi: 10.1002/(SICI)1097-0142(19980915)83:6<1109::AID-CNCR9>3.0.CO;2-2. - DOI - PubMed
    1. National Lung Screening Trial Research Team. Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., Gareen I.F., Gatsonis C., Marcus P.M., et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N. Engl. J. Med. 2011;365:395–409. doi: 10.1056/NEJMoa1102873. - DOI - PMC - PubMed